Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02384096 · ClinicalTrials.gov registry record · NA
A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes
A NA study, sponsored by Boston Scientific Corporation.
- Terminated
- Registry status
- NA
- Development phase
- 17
- Enrollment target
NCT02384096 is a NA study that was terminated before completion, run by Boston Scientific Corporation. The registered enrollment target is 17 participants.
The verdict
NCT02384096, a NA study, was terminated before completion, sponsored by Boston Scientific Corporation.
- TERMINATED
- Registry status
- NA
- Development phase
- 17 participants
- Enrollment target
Study Summary
The study is a prospective, on-label, multi-center, blinded, randomized controlled trial with a cross-over design to evaluate the effect of Precision Spectra™ SCS System's programming features and lead options.
Interventions
- DEVICE Conventional single source programming
- DEVICE Precision Spectra SCS System advanced programming
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 17 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-10 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02384096
The ClinicalTrials.gov registry entry for NCT02384096 describes a study currently listed as terminated, categorized as NA. The registered enrollment target is 17 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Boston Scientific Corporation, which has 280 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Conventional single source programming is the first listed.
NCT02384096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02384096 about?
NCT02384096 is a clinical study titled "A Study to Evaluate the Effect of Precision Spectra™ Programming Features and Lead Options on Patient Outcomes". The study is a prospective, on-label, multi-center, blinded, randomized controlled trial with a cross-over design to evaluate the effect of Precision Spectra™ SCS System's programming features and lead options.
What is the current status of trial NCT02384096?
This trial is currently terminated. It is a NA study. The enrollment target is 17 participants. The study started on 2015-02. Estimated completion is 2016-10.
What interventions are being tested in trial NCT02384096?
The interventions under investigation include: Conventional single source programming (DEVICE), Precision Spectra SCS System advanced programming (DEVICE).
Who is sponsoring clinical trial NCT02384096?
This trial is sponsored by Boston Scientific Corporation, which has 280 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.